SLC13A3 variants cause acute reversible leukoencephalopathy and α-ketoglutarate accumulation.


Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
03 2019
Historique:
received: 20 07 2018
revised: 08 01 2019
accepted: 08 01 2019
pubmed: 13 1 2019
medline: 14 1 2020
entrez: 13 1 2019
Statut: ppublish

Résumé

SLC13A3 encodes the plasma membrane Na Whole exome sequencing (WES) was performed. Our teams were connected through GeneMatcher. WES analysis revealed variants in SLC13A3. A homozygous missense mutation (p.Ala254Asp) was found in the first patient. The second patient was heterozygous for another missense mutation (p.Gly548Ser) and an intronic mutation affecting splicing as demonstrated by reverse transcriptase polymerase chain reaction performed in muscle tissue (c.1016 + 3A > G). Mutations and segregation were confirmed by Sanger sequencing. Functional studies performed on HEK293T cells transiently transfected with wild-type and mutant SLC13A3 indicated that the missense mutations caused a marked reduction in the capacity to transport αKG, succinate, and NAA. SLC13A3 deficiency causes acute and reversible leukoencephalopathy with marked accumulation of αKG. Urine organic acids (especially αKG and NAA) and SLC13A3 mutations should be screened in patients presenting with unexplained reversible leukoencephalopathy, for which SLC13A3 deficiency is a novel differential diagnosis. ANN NEUROL 2019;85:385-395.

Identifiants

pubmed: 30635937
doi: 10.1002/ana.25412
doi:

Substances chimiques

Ketoglutaric Acids 0
SLC13A3 protein, human 0
Symporters 0
Aspartic Acid 30KYC7MIAI
N-acetylaspartate 997-55-7
Succinic Acid AB6MNQ6J6L

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

385-395

Subventions

Organisme : Association Européenne contre les Leucodystrophies
ID : ELA 2009-007I4
Pays : International
Organisme : European Union FP7 RD Connect project
ID : ELA 2009-007I4
Pays : International
Organisme : Fonds De La Recherche Scientifique - FNRS
Pays : International
Organisme : Walloon Excellence in Life sciences and Biotechnology (WELBIO)
Pays : International
Organisme : NIH HHS
ID : R01 GM108911
Pays : United States
Organisme : European Leukodystrophy Association
Pays : International
Organisme : Walloon Excellence in Life sciences and Biotechnology (WELBIO)
Pays : International
Organisme : National Fund for Scientific Research
Pays : International

Informations de copyright

© 2019 American Neurological Association.

Auteurs

Joseph P Dewulf (JP)

Laboratory of Physiological Chemistry, de Duve Institute, Université catholique de Louvain, Brussels, Belgium.
Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Brussels, Belgium.
Department of Laboratory Medicine, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.

Elsa Wiame (E)

Laboratory of Physiological Chemistry, de Duve Institute, Université catholique de Louvain, Brussels, Belgium.
Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Brussels, Belgium.

Imen Dorboz (I)

UMR1141, PROTECT, INSERM, Paris Diderot University, Sorbonne Paris Cité, Paris, France.

Monique Elmaleh-Bergès (M)

Department of Pediatric Imaging, Robert Debré University Hospital, Public APHP, Paris, France.

Apolline Imbard (A)

Laboratory of Biochemistry, Robert Debré University Hospital, APHP, France.
Paris-Sud University, Châtenay-Malabry, France.

Dana Dumitriu (D)

Department of Pediatric Imaging, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.

Malgorzata Rak (M)

UMR1141, PROTECT, INSERM, Paris Diderot University, Sorbonne Paris Cité, Paris, France.

Agnès Bourillon (A)

Laboratory of Biochemistry, Robert Debré University Hospital, APHP, France.
Paris-Sud University, Châtenay-Malabry, France.

Raphaël Helaers (R)

Human Molecular Genetics, de Duve Institute, Université catholique de Louvain, Brussels, Belgium.

Alisha Malla (A)

Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.

Florence Renaldo (F)

UMR1141, PROTECT, INSERM, Paris Diderot University, Sorbonne Paris Cité, Paris, France.
Department of Pediatric Neurology and Metabolic Diseases, Robert Debré University Hospital, APHP, Paris, France.
Reference Center for Leukodystrophies and Rare Leukoencephalopathies, LEUKOFRANCE, Robert Debré University Hospital, APHP, Paris, France.

Odile Boespflug-Tanguy (O)

UMR1141, PROTECT, INSERM, Paris Diderot University, Sorbonne Paris Cité, Paris, France.
Department of Pediatric Neurology and Metabolic Diseases, Robert Debré University Hospital, APHP, Paris, France.
Reference Center for Leukodystrophies and Rare Leukoencephalopathies, LEUKOFRANCE, Robert Debré University Hospital, APHP, Paris, France.

Marie-Françoise Vincent (MF)

Department of Laboratory Medicine, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.

Jean-François Benoist (JF)

Laboratory of Biochemistry, Robert Debré University Hospital, APHP, France.
Paris-Sud University, Châtenay-Malabry, France.

Ron A Wevers (RA)

Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.

Avner Schlessinger (A)

Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.

Emile Van Schaftingen (E)

Laboratory of Physiological Chemistry, de Duve Institute, Université catholique de Louvain, Brussels, Belgium.
Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Brussels, Belgium.

Marie-Cécile Nassogne (MC)

Pediatric Neurology Unit, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.

Manuel Schiff (M)

UMR1141, PROTECT, INSERM, Paris Diderot University, Sorbonne Paris Cité, Paris, France.
Department of Pediatric Neurology and Metabolic Diseases, Robert Debré University Hospital, APHP, Paris, France.
Reference Center for Inborn Errors of Metabolism, Robert Debré University Hospital, APHP, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH